Table 2.
Registry participant eligibility for currently enrolling ADPKD clinical trials
| Compound and ClinicalTrials.gov Identifier | Relevant Eligibility Criteria | Number of Potentially Eligible Registry Participants | ||
|---|---|---|---|---|
| Age, yr | eGFR, ml/min per 1.73 m2 | BMI, kg/m2 | ||
| Bardoxolone methyl (NCT03918447) | 18–70 | 30–90 | >18.5 | 1097 |
| Caloric restriction (NCT04534985) | 18–65 | >30 | 25–45 | 337 |
| Lixivaptan—ACTION (NCT04064346) | 18–60 | 25–90 | 18–40 | 1101 |
| Lixivaptan—The ALERT Study (NCT04152837) | 18–65 | >20 | 18–35 | 1109 |
| Pravastatin (NCT03273413) | 25–60 | >60 | n/a | 788 |
| RGLS4326 (NCT04536688) | 18–70 | 30–90 | 18–35 | 1097 |
Study inclusion criteria accurate as of October 12, 2021. Counts of those with unknown eGFR values were included if they met other eligibility criteria (e.g., age, no history of kidney transplant or dialysis). This is not intended to be a comprehensive list, and only includes those studies with open enrollment in October 2021 in the United States, studying ADPKD exclusively and those with current collaborative recruitment efforts with the PKD Foundation. ADPDK, autosomal dominant polycystic kidney disease.